HER2-positive male breast cancer: an update

References

• KordeLAZujewskiJAKaminLMultidisciplinary meeting on male breast cancer: summary and research recommendationsJ Clin Oncol201028122114212220308661
   PubMed Web of Science ®Google Scholar
• Cancer incidence in five continentsIARC Sci Publ19761583
   Google Scholar
• WeissJRMoysichKBSwedeHEpidemiology of male breast cancerCancer Epidemiol Biomarkers Prev200514202615668471
   PubMed Web of Science ®Google Scholar
• StangAThomssenCDecline in breast cancer incidence in the United States: what about male breast cancer?Breast Cancer Res Treat200811259559618176840
   PubMed Web of Science ®Google Scholar
• ContractorKBKaurKRodriguesGSKulkarniDMSinghalHMale breast cancer: is the scenario changingWorld J Surg Oncol200865818558006
   PubMed Web of Science ®Google Scholar
• BhagwandeenSBCarcinoma of the male breast in ZambiaEast Afr Med J19724989935047279
   PubMedGoogle Scholar
• OjaraEACarcinoma of the male breast in Mulago Hospital, KampalaEast Afr Med J197855489491738189
   PubMed Web of Science ®Google Scholar
• MabuchiKBrossDSKesslerIIRisk factors for male breast cancerJ Natl Cancer Inst1985743713753856050
   PubMedGoogle Scholar
• SpeirsVShaabanAMThe rising incidence of male breast cancerBreast Cancer Res Treat200911542943018478326
   PubMed Web of Science ®Google Scholar
• GiordanoSHBuzdarAUHortobagyiGNBreast cancer in menAnn Intern Med200213767868712379069
   PubMed Web of Science ®Google Scholar
• AndersonWFJatoiITseJRosenbergPSMale breast cancer: a population-based comparison with female breast cancerJ Clin Oncol20102823223919996029
   PubMed Web of Science ®Google Scholar
• CoardKMcCartneyTBilateral synchronous carcinoma of the male breast in a patient receiving estrogen therapy for carcinoma of the prostate: cause or coincidence?South Med J20049730831015043344
   PubMed Web of Science ®Google Scholar
• GanlyITaylorEWBreast cancer in a trans-sexual man receiving hormone replacement therapyBr J Surg1995823417796003
   PubMed Web of Science ®Google Scholar
• KaramanakosPMitsiadesCSLembessisPKontosMTrafalisDKoutsilierisMMale breast adenocarcinoma in a prostate cancer patient following prolonged anti-androgen monotherapyAnticancer Res2004241077108115154626
   PubMed Web of Science ®Google Scholar
• ThomasDBRosenblattKJimenezLMIonizing radiation and breast cancer in men (United States)Cancer Causes Control199459148123783
   PubMed Web of Science ®Google Scholar
• PalliDMasalaGMariani-CostantiniRA gene-environment interaction between occupation and BRCA1/BRCA2 mutations in male breast cancer?Eur J Cancer2004402474247915519522
   PubMed Web of Science ®Google Scholar
• BashamVMLipscombeJMWardJMBRCA1 and BRCA2 mutations in a population-based study of male breast cancerBreast Cancer Res20024R211879560
   PubMed Web of Science ®Google Scholar
• CasagrandeJTHanischRPikeMCRossRKBrownJBHendersonBEA case-control study of male breast cancerCancer Res198848132613303342411
   PubMed Web of Science ®Google Scholar
• EwertzMHolmbergLTretliSPedersenBVKristensenARisk factors for male breast cancer – a case-control study from ScandinaviaActa Oncol20014046747111504305
   PubMed Web of Science ®Google Scholar
• JohnsonKCPanSMaoYRisk factors for male breast cancer in Canada, 1994–1998Eur J Cancer Prev20021125326312131659
   PubMed Web of Science ®Google Scholar
• Lenfant-PejovicMHMlika-CabanneNBouchardyCAuquierARisk factors for male breast cancer: a Franco-Swiss case-control studyInt J Cancer1990456616652323842
   PubMed Web of Science ®Google Scholar
• PalliDFalchettiMMasalaGAssociation between the BRCA2 N372H variant and male breast cancer risk: a population-based case-control study in Tuscany, Central ItalyBMC Cancer2007717017767707
   PubMed Web of Science ®Google Scholar
• RosenblattKAThomasDBMcTiernanABreast cancer in men: aspects of familial aggregationJ Natl Cancer Inst1991838498542061945
   PubMedGoogle Scholar
• Satram-HoangSZiogasAAnton-CulverHRisk of second primary cancer in men with breast cancerBreast Cancer Res20079R1017254323
   PubMed Web of Science ®Google Scholar
• AuvinenACurtisRERonERisk of subsequent cancer following breast cancer in menJ Natl Cancer Inst2002941330133212208898
   PubMedGoogle Scholar
• BroetPde la RochefordiereASchollSMContralateral breast cancer: annual incidence and risk parametersJ Clin Oncol199513157815837602346
   PubMed Web of Science ®Google Scholar
• GiordanoSHA review of the diagnosis and management of male breast cancerOncologist20051047147916079314
   PubMed Web of Science ®Google Scholar
• LiedeANarodSAHereditary breast and ovarian cancer in Asia: genetic epidemiology of BRCA1 and BRCA2Hum Mutat20022041342412442265
   PubMed Web of Science ®Google Scholar
• BaudiFQuaresimaBGrandinettiCEvidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancerHum Mutat20011816316411462242
   PubMedGoogle Scholar
• FerlaRCaloVCascioSFounder mutations in BRCA1 and BRCA2 genesAnn Oncol200718Suppl 6vi93vi9817591843
   PubMed Web of Science ®Google Scholar
• MalacridaSAgataSCallegaroMBRCA1 p.Val1688del is a deleterious mutation that recurs in breast and ovarian cancer families from Northeast ItalyJ Clin Oncol200826263118165637
   PubMed Web of Science ®Google Scholar
• OttiniLRizzoloPZannaIBRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central ItalyBreast Cancer Res Treat200911657758618819001
   PubMed Web of Science ®Google Scholar
• PapiLPutignanoALCongregatiCFounder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central ItalyBreast Cancer Res Treat200911749750418821011
   PubMed Web of Science ®Google Scholar
• PisanoMCossuAPersicoIIdentification of a founder BRCA2 mutation in SardiniaBr J Cancer20008255355910682665
   PubMed Web of Science ®Google Scholar
• RussoACaloVBrunoLIs BRCA1-5083del19, identified in breast cancer patients of Sicilian origin, a Calabrian founder mutation?Breast Cancer Res Treat2009113677018228134
   PubMed Web of Science ®Google Scholar
• EvansDGBulmanMYoungKBRCA1/2 mutation analysis in male breast cancer families from North West EnglandFam Cancer2008711311717636422
   PubMed Web of Science ®Google Scholar
• MioloGPuppaLDSantarosaMPhenotypic features and genetic characterization of male breast cancer families: identification of two recurrent BRCA2 mutations in north-east of ItalyBMC Cancer2006615616764716
   PubMed Web of Science ®Google Scholar
• GiordanoSHCohenDSBuzdarAUPerkinsGHortobagyiGNBreast carcinoma in men: a population-based studyCancer2004101515715221988
   PubMed Web of Science ®Google Scholar
• NahlehZASrikantiahRSafaMJaziehARMuhlemanAKomrokjiRMale breast cancer in the veterans affairs population: a comparative analysisCancer20071091471147717342768
   PubMed Web of Science ®Google Scholar
• OttiniLPalliDRizzoSFedericoMBazanVRussoAMale breast cancerCrit Rev Oncol Hematol20107314115519427229
   PubMed Web of Science ®Google Scholar
• SanchezAGVillanuevaAGRedondoCLobular carcinoma of the breast in a patient with Klinefelter’s syndrome. A case with bilateral, synchronous, histologically different breast tumorsCancer198657118111833002597
   PubMed Web of Science ®Google Scholar
• StalsbergHThomasDBRosenblattKAHistologic types and hormone receptors in breast cancer in men: a population-based study in 282 United States menCancer Causes Control199341431518386948
   PubMed Web of Science ®Google Scholar
• FentimanISFourquetAHortobagyiGNMale breast cancerLancet200636759560416488803
   PubMed Web of Science ®Google Scholar
• Meijer-van GelderMELookMPBolt-de VriesJPetersHAKlijnJGFoekensJAClinical relevance of biologic factors in male breast cancerBreast Cancer Res Treat20016824926011727961
   PubMed Web of Science ®Google Scholar
• Munoz de ToroMMMaffiniMVKassLLuqueEHProliferative activity and steroid hormone receptor status in male breast carcinomaJ Steroid Biochem Mol Biol1998673333399883990
   PubMed Web of Science ®Google Scholar
• GeYSneigeNEltorkyMAImmunohistochemical characterization of subtypes of male breast carcinomaBreast Cancer Res200911R2819442295
   PubMed Web of Science ®Google Scholar
• RudlowskiCFriedrichsNFaridiAHer-2/neu gene amplification and protein expression in primary male breast cancerBreast Cancer Res Treat20048421522315026619
   PubMed Web of Science ®Google Scholar
• BloomKJGovilHGattusoPReddyVFrancescattiDStatus of HER-2 in male and female breast carcinomaAm J Surg200118238939211720677
   PubMed Web of Science ®Google Scholar
• MuirDKanthanRKanthanSCMale versus female breast cancers. A population-based comparative immunohistochemical analysisArch Pathol Lab Med2003127364112521364
   PubMed Web of Science ®Google Scholar
• CareyLAPerouCMLivasyCARace, breast cancer subtypes, and survival in the Carolina Breast Cancer StudyJAMA2006295212492250216757721
   PubMed Web of Science ®Google Scholar
• AndersonWFAlthuisMDBrintonLADevesaSSIs male breast cancer similar or different than female breast cancer?Breast Cancer Res Treat200483778614997057
   PubMed Web of Science ®Google Scholar
• GolshanMRusbyJDominguezFSmithBLBreast conservation for male breast carcinomaBreast20071665365617606375
   PubMed Web of Science ®Google Scholar
• DimitrovNVColucciPNagpalSSome aspects of the endocrine profile and management of hormone-dependent male breast cancerOncologist20071279880717673611
   PubMed Web of Science ®Google Scholar
• GiordanoSHValeroVBuzdarAUHortobagyiGNEfficacy of anastrozole in male breast cancerAm J Clin Oncol20022523523712040279
   PubMed Web of Science ®Google Scholar
• KraybillWGKaufmanRKinneDTreatment of advanced male breast cancerCancer198147218521896164479
   PubMed Web of Science ®Google Scholar
• BaselgaJSwainSMNovel anticancer targets: revisiting ERBB2 and discovering ERBB3Nat Rev Cancer2009946347519536107
   PubMed Web of Science ®Google Scholar
• UberallIKolarZTrojanecRBerkovcovaJHajduchMThe status and role of ErbB receptors in human cancerExp Mol Pathol200884798918279851
   PubMed Web of Science ®Google Scholar
• YardenYSliwkowskiMXUntangling the ErbB signalling networkNat Rev Mol Cell Biol2001212713711252954
   PubMed Web of Science ®Google Scholar
• KarunagaranDTzaharEBeerliRRErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancerEmbo J1996152542648617201
   PubMed Web of Science ®Google Scholar
• OlayioyeMANeveRMLaneHAHynesNEThe ErbB signaling network: receptor heterodimerization in development and cancerEmbo J2000193159316710880430
   PubMed Web of Science ®Google Scholar
• OffterdingerMBastiaensPIProlonged EGFR signaling by ERBB2-mediated sequestration at the plasma membraneTraffic2008914715517956594
   PubMed Web of Science ®Google Scholar
• CiampaAXuBAyataGHER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging systemAppl Immunohistochem Mol Morphol20061413213716785779
   PubMedGoogle Scholar
• LeeJWSoungYHSeoSHSomatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomasClin Cancer Res200612576116397024
   PubMed Web of Science ®Google Scholar
• MengSTripathyDSheteSHER-2 gene amplification can be acquired as breast cancer progressesProc Natl Acad Sci U S A20041019393939815194824
   PubMed Web of Science ®Google Scholar
• BianchiSPalliDFalchettiMErbB-receptors expression and survival in breast carcinoma: a 15-year follow-up studyJ Cell Physiol200620670270816245316
   PubMed Web of Science ®Google Scholar
• CastiglioniFTagliabueECampiglioMPupaSMBalsariAMenardSRole of exon-16-deleted HER2 in breast carcinomasEndocr Relat Cancer20061322123216601290
   PubMed Web of Science ®Google Scholar
• KwongKYHungMCA novel splice variant of HER2 with increased transformation activityMol Carcinog19982362689808159
   PubMed Web of Science ®Google Scholar
• PichAMargariaEChiusaLOncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survivalJ Clin Oncol2000182948295610944127
   PubMed Web of Science ®Google Scholar
• Wang-RodriguezJCrossKGallagherSMale breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 casesMod Pathol20021585386112181271
   PubMed Web of Science ®Google Scholar
• FonsecaRRTomasARAndreSSoaresJEvaluation of ERBB2 gene status and chromosome 17 anomalies in male breast cancerAm J Surg Pathol2006301292129817001161
   PubMed Web of Science ®Google Scholar
• HonradoEOsorioAPalaciosJBenitezJPathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutationsOncogene2006255837584516998498
   PubMed Web of Science ®Google Scholar
• SpectorNLBlackwellKLUnderstanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancerJ Clin Oncol2009275838584719884552
   PubMed Web of Science ®Google Scholar
• Product monograph: HerceptinΔ (trastuzumab)Genetech IncUSA32009
   Google Scholar
• Product monograph: HerceptinΔ (trastuzumab)Hoffmann-La Roche Limited200811 4
   Google Scholar
• ClynesRATowersTLPrestaLGRavetchJVInhibitory Fc receptors modulate in vivo cytoxicity against tumor targetsNat Med2000644344610742152
   PubMed Web of Science ®Google Scholar
• GennariRMenardSFagnoniFPilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2Clin Cancer Res2004105650565515355889
   PubMed Web of Science ®Google Scholar
• WeinerLMAdamsGPNew approaches to antibody therapyOncogene2000196144615111156528
   PubMed Web of Science ®Google Scholar
• HudisCATrastuzumab – mechanism of action and use in clinical practiceN Engl J Med2007357395117611206
   PubMed Web of Science ®Google Scholar
• MolinaMACodony-ServatJAlbanellJRojoFArribasJBaselgaJTrastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cellsCancer Res2001614744474911406546
   PubMed Web of Science ®Google Scholar
• LeXFLammayotAGoldDGenes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signalingJ Biol Chem20052802092210415504738
   PubMed Web of Science ®Google Scholar
• LeXFClaretFXLammayotAThe role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibitionJ Biol Chem2003278234412345012700233
   PubMed Web of Science ®Google Scholar
• NagataYLanKHZhouXPTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell2004611712715324695
   PubMed Web of Science ®Google Scholar
• IzumiYXuLdi TomasoEFukumuraDJainRKTumour biology: herceptin acts as an anti-angiogenic cocktailNature200241627928011907566
   PubMed Web of Science ®Google Scholar
• ValabregaGMontemurroFSarottoITGFalpha expression impairs trastuzumab-induced HER2 downregulationOncogene2005243002301015735715
   PubMed Web of Science ®Google Scholar
• PrempreeTWongpaksaCMutations of HER2 gene in HER2-positive metastatic breast cancerJ Clin Oncol200624Suppl 18 (Abstract 13118)
   Web of Science ®Google Scholar
• HynesNEDeyJHPI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enoughCancer Cell20091535335519411062
   PubMed Web of Science ®Google Scholar
• LuCHWyszomierskiSLTsengLMPreclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiencyClin Cancer Res2007135883588817908983
   PubMed Web of Science ®Google Scholar
• NagyPFriedlanderETannerMDecreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell lineCancer Res20056547348215695389
   PubMed Web of Science ®Google Scholar
• LuYZiXZhaoYMascarenhasDPollakMInsulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)J Natl Cancer Inst2001931852185711752009
   PubMed Web of Science ®Google Scholar
• NahtaRYuanLXZhangBKobayashiREstevaFJInsulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cellsCancer Res200565111181112816322262
   PubMed Web of Science ®Google Scholar
• CobleighMAVogelCLTripathyDMultinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic diseaseJ Clin Oncol1999172639264810561337
   PubMed Web of Science ®Google Scholar
• MartyMCognettiFMaraninchiDRandomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study groupJ Clin Oncol2005234265427415911866
   PubMed Web of Science ®Google Scholar
• SlamonDJLeyland-JonesBShakSUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med200134478379211248153
   PubMed Web of Science ®Google Scholar
• VogelCLCobleighMATripathyDEfficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancerJ Clin Oncol20022071972611821453
   PubMed Web of Science ®Google Scholar
• SuterTMCook-BrunsNBartonCCardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancerBreast20041317318315177418
   PubMed Web of Science ®Google Scholar
• BaselgaJHerceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trialsOncology200161Suppl 2142111694783
   PubMed Web of Science ®Google Scholar
• AmarSRoyVPerezEATreatment of metastatic breast cancer: looking towards the futureBreast Cancer Res Treat200911441342218465221
   PubMed Web of Science ®Google Scholar
• RudlowskiCRathWBeckerAJWiestlerODButtnerRTrastuzumab and breast cancerN Engl J Med200134599799811575298
   PubMed Web of Science ®Google Scholar
• Carmona-BayonasAPotential benefit of maintenance trastuzumab and anastrozole therapy in male advanced breast cancerBreast20071632332517292609
   PubMed Web of Science ®Google Scholar
• HayashiHKimuraMYoshimotoNA case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatmentBreast Cancer20091613614018548321
   PubMed Web of Science ®Google Scholar
• NCCN (National Comprehensive Cancer Network) Available from: http://www.nccn.org
   Google Scholar
• Cancer.gov Available from: http://www.cancer.gov/cancertopics/pdq/treatment/malebreast
   Google Scholar
• JoensuuHKellokumpu-LehtinenPLBonoPAdjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancerN Engl J Med200635480982016495393
   PubMed Web of Science ®Google Scholar
• Piccart-GebhartMJProcterMLeyland-JonesBTrastuzumab after adjuvant chemotherapy in HER2-positive breast cancerN Engl J Med20053531659167216236737
   PubMed Web of Science ®Google Scholar
• RomondEHPerezEABryantJTrastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerN Engl J Med20053531673168416236738
   PubMed Web of Science ®Google Scholar
• SmithIProcterMGelberRD2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trialLancet2007369293617208639
   PubMed Web of Science ®Google Scholar
• Leyland-JonesBGelmonKAyoubJPPharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxelJ Clin Oncol2003213965397114507946
   PubMed Web of Science ®Google Scholar
• McEvoyGAHFS Drug Information2001
   Google Scholar
• MackeyJRClemonsMCoteMACardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working GroupCurr Oncol200815243518317582
   PubMed Web of Science ®Google Scholar
• SuterTMProcterMvan VeldhuisenDJTrastuzumab-associated cardiac adverse effects in the herceptin adjuvant trialJ Clin Oncol2007253859386517646669
   PubMed Web of Science ®Google Scholar
• Tan-ChiuEYothersGRomondEAssessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31J Clin Oncol2005237811781916258083
   PubMed Web of Science ®Google Scholar
• PerezEASumanVJDavidsonNECardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trialJ Clin Oncol2008261231123818250349
   PubMed Web of Science ®Google Scholar
• KonecnyGEPegramMDVenkatesanNActivity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cellsCancer Res20066631630163916452222
   PubMed Web of Science ®Google Scholar
• ScheuerWFriessTBurtscherHBossenmaierBEndlJHasmannMStrongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor modelsCancer Res200969249330933619934333
   PubMed Web of Science ®Google Scholar